dry powder comprises microparticles with Mass Median Aerodynamic Diameter (MMAD) of 1 to 5 microns. According to another embodiment, the therapeutic amount of the pharmaceutical composition is administered via an inhalation device. According to another embodiment, the inhalation device is a nebulizer. According to another embodiment, the inhalation device is a metered-dose inhaler (MDI). According to another embodiment, the inhalation device is a dry powder inhaler (DPI).

[00140a] According to an aspect, the present disclosure provides the use of a pharmaceutical composition in the manufacture of a medicament for delivery to lung tissue of a subject for therapeutic treatment of a lung disease or condition, the lung disease or condition comprising a pulmonary fibrosis comprising one or more of an aberrant deposition of collagen in a pulmonary interstitium, an aberrant promotion of fibroblast proliferation in the lung, an aberrant induction of myofibroblast differentiation in the lung, and/or an aberrant promotion of attachment of myofibroblasts to an extracellular matrix compared to a normal healthy control subject, wherein the lung tissue is characterized by an aberrant activity of Mitogen-Activated Protein Kinase- Activated Protein Kinase 2 (MK2) in the tissue compared to the activity of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) in the tissue of a normal healthy control subject,

wherein the pharmaceutical composition is in a form for delivery by inhalation,

wherein the pharmaceutical composition comprises a therapeutic amount of a polypeptide of the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1), or a functional equivalent thereof, wherein the functional equivalent is, a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 3); or a polypeptide of amino acid sequence KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 4); or a polypeptide of amino acid sequence HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 7), and a pharmaceutically acceptable carrier thereof, wherein the carrier is selected from the group consisting of a controlled release carrier, a delayed release carrier, a sustained release carrier, and a long-term release carrier and

wherein the therapeutic amount is effective to reduce one or more of:

(i) development of fibrotic foci in the lung;

(ii) collagen accumulation in the lung; or

inhibited more than 65% by MMI-0100 (YARAAARQARAKALARQLGVAA; SEQ ID NO: 1); MMI-0200 (YARAAARQARAKALNRQLGVA; SEQ ID NO: 19); MMI-0300 (FAKLAARLYRKALARQLGVAA; SEQ ID NO: 3); MMI-0400 (KAFAKLAARLYRKALARQLGVAA; SEQ ID NO: 4); and MMI-0500 (HRRIKAWLKKIKALARQLGVAA; SEQ ID NO: 7) were determined.

[00598] As shown in **Table 1,** at 100 μM, MK2 inhibitory peptides MMI-0100 (SEQ ID NO: 1), MMI-0200 (SEQ ID NO: 19), MMI-0300 (SEQ ID NO: 3); MMI-0400 (SEQ ID NO: 4); and MMI-0500 (SEQ ID NO: 7) inhibited a specific group of kinases and showed very limited off-target kinase inhibition. More specifically, MK2 inhibitory peptides MMI-0100 (SEQ ID NO: 1), MMI-0200 (SEQ ID NO: 19), MMI-0300 (SEQ ID NO: 3); MMI-0400 (SEQ ID NO: 4); and MMI-0500 (SEQ ID NO: 7) inhibited *in vitro* more than 65% of the kinase activities of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2), Mitogen-Activated Protein Kinase-Activated Protein Kinase 3 (MK3), Calcium/Calmodulin-Dependent Protein Kinase I (CaMKI, serine/threonine-specific protein kinase), and BDNF/NT-3 growth factors receptor (TrkB, tyrosine kinase).

[00599] **Table 1. Kinase Profiling Assay**

	MMI-0100 (SEQ ID NO: 1) (100 μM)	MMI-0200 (SEQ ID NO: 19) (100 μM)	MMI-0300 (SEQ ID NO: 3) (100 μM)	MMI-0400 (SEQ ID NO: 4) (100 μM)	MMI-0500 (SEQ ID NO: 7) (100 μM)
Abl(h)	136	107	69	84	16
Abl (H396P) (h)	130	121	101	105	51
Abl (M351T)(h)	128	119	90	121	61
Abl (Q252H) (h)	105	107	82	98	40
Abl(T315I)(h)	98	108	97	105	16
Abl(Y253F)(h)	104	102	86	78	29
ACK1(h)	106	97	104	95	64
ALK(h)	118	95	19	16	12
ALK4(h)	124	152	140	130	81
Arg(h)	89	82	72	84	22
AMPKα1(h)	107	108	71	87	35
AMPKα2(h)	121	88	54	58	9
ARK5(h)	108	93	78	69	20
ASK1(h)	100	101	80	69	-4
Aurora-A(h)	120	107	92	119	110
Aurora-B(h)	94	166	128	150	5
Axl(h)	81	99	52	41	12
Bmx(h)	62	76	N/D	26	45
BRK(h)	70	127	35	18	41
BrSK1(h)	100	93	67	76	72

CLAIMS

We claim:

1. Use of a pharmaceutical composition in the manufacture of a medicament for delivery to lung tissue of a subject for therapeutic treatment of a lung disease or condition, the lung disease or condition comprising a pulmonary fibrosis comprising one or more of an aberrant deposition of collagen in a pulmonary interstitium, an aberrant promotion of fibroblast proliferation in the lung, an aberrant induction of myofibroblast differentiation in the lung, and/or an aberrant promotion of attachment of myofibroblasts to an extracellular matrix compared to a normal healthy control subject, wherein the lung tissue is characterized by an aberrant activity of Mitogen-Activated Protein Kinase- Activated Protein Kinase 2 (MK2) in the tissue compared to the activity of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) in the tissue of a normal healthy control subject,

wherein the pharmaceutical composition is in a form for delivery by inhalation,

wherein the pharmaceutical composition comprises a therapeutic amount of a polypeptide of the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1), or a functional equivalent thereof, wherein the functional equivalent is, a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 3); or a polypeptide of amino acid sequence KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 4); or a polypeptide of amino acid sequence HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 7), and a pharmaceutically acceptable carrier thereof, wherein the carrier is selected from the group consisting of a controlled release carrier, a delayed release carrier, a sustained release carrier, and a long-term release carrier and

wherein the therapeutic amount is effective to reduce one or more of:

(i) development of fibrotic foci in the lung;

(ii) collagen accumulation in the lung; or

(iii) progression of collagen deposition in the lung compared to a control vehicle.

2. The use of claim 1, wherein the therapeutic amount is effective to inhibit kinase activity of a kinase selected from the group of a Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) and a Mitogen-Activated Protein Kinase-Activated Protein Kinase 3 (MK3).